Cargando…

Neoadjuvant metformin added to conventional chemotherapy synergizes anti-proliferative effects in ovarian cancer

BACKGROUND: Ovarian cancer is the leading cause of cancer-related death among women. Complete cytoreductive surgery followed by platinum-taxene chemotherapy has been the gold standard for a long time. Various compounds have been assessed in an attempt to combine them with conventional chemotherapy t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wen, Kuo-Chang, Sung, Pi-Lin, Wu, Alexander T. H., Chou, Ping-Chieh, Lin, Jun-Hung, Huang, Chi-Ying F., Yeung, Sai-Ching J., Lee, Mong-Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7442990/ https://www.ncbi.nlm.nih.gov/pubmed/32825834 http://dx.doi.org/10.1186/s13048-020-00703-x

Ejemplares similares

Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer
por: Lopez-Bonet, Eugeni, et al.
Publicado: (2019)

Pramlintide, an antidiabetic, is antineoplastic in colorectal cancer and synergizes with conventional chemotherapy
por: Al-Keilani, Maha S, et al.
Publicado: (2018)

Maintenance Therapy Containing Metformin and/or Zyflamend for Advanced Prostate Cancer: A Case Series
por: Bilen, Mehmet Asim, et al.
Publicado: (2015)

Emerging Trends in Neoadjuvant Chemotherapy for Ovarian Cancer
por: Patel, Ami, et al.
Publicado: (2021)

Metformin and erlotinib synergize to inhibit basal breast cancer
por: Lau, Ying-Ka Ingar, et al.
Publicado: (2014)

Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation
por: Groenendijk, Floris H, et al.
Publicado: (2015)

Neoadjuvant chemotherapy for Patients with advanced epithelial ovarian cancer: A Meta-Analysis
por: Zeng, Long-Jia, et al.
Publicado: (2016)

The added value of CA125 normalization before interval debulking surgery to the chemotherapy response score for the prognostication of ovarian cancer patients receiving neoadjuvant chemotherapy for advanced disease
por: Liang, Wei-feng, et al.
Publicado: (2021)

Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma
por: Hegazy, Mohamed AF, et al.
Publicado: (2005)

Role of Neoadjuvant Chemotherapy in Ovarian Serous Cancer Followed by Debulking
por: Chauhan, Sonali, et al.
Publicado: (2022)

Improved T-cell Immunity Following Neoadjuvant Chemotherapy in Ovarian Cancer
por: Liu, Min, et al.
Publicado: (2022)

Neoadjuvant chemotherapy in advanced-stage ovarian cancer – state of the art
por: Margioula-Siarkou, Chrysoula, et al.
Publicado: (2022)

Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI
por: Guo, J, et al.
Publicado: (2015)

Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer
por: Wan, Guoxing, et al.
Publicado: (2019)

Adjuvant chemotherapy and survival outcomes in rectal cancer patients with good response (ypT0-2N0) after neoadjuvant chemoradiotherapy and surgery: A retrospective nationwide analysis
por: Kuo, Yu-Hsuan, et al.
Publicado: (2022)

Synergic Effect of Metformin and Everolimus on Mitochondrial Dynamics of Renal Cell Carcinoma
por: Hong, Seong-Hwi, et al.
Publicado: (2022)

The AKT Inhibitor MK-2206 is Cytotoxic in Hepatocarcinoma Cells Displaying Hyperphosphorylated AKT-1 and Synergizes with Conventional Chemotherapy
por: Simioni, Carolina, et al.
Publicado: (2013)

Predictors of Survival in Esophageal Squamous Cell Carcinoma with Pathologic Major Response after Neoadjuvant Chemoradiation Therapy and Surgery: The Impact of Chemotherapy Protocols
por: Li, Chia-Ying, et al.
Publicado: (2016)

Probiotics synergized with conventional regimen in managing Parkinson’s disease
por: Sun, Hairong, et al.
Publicado: (2022)

Metformin prevents nerve growth factor-dependent proliferative and proangiogenic effects in epithelial ovarian cancer cells and endothelial cells
por: Garrido, Maritza P., et al.
Publicado: (2018)

The role of neoadjuvant chemotherapy in ovarian cancer patients with extensive tumor burden
por: Kang, Sokbom
Publicado: (2011)

Tissue Biomarkers in Prognostication of Serous Ovarian Cancer following Neoadjuvant Chemotherapy
por: Khandakar, Binny, et al.
Publicado: (2014)

Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A survival study
por: Baruah, Upasana, et al.
Publicado: (2015)

Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancer
por: Mizuno, Takaaki, et al.
Publicado: (2020)

The Evaluation Value of CT in the Efficacy of Neoadjuvant Chemotherapy in Ovarian Cancer Patients
por: Mou, Daying, et al.
Publicado: (2022)

No survival benefit from adding chemotherapy to adjuvant radiation in advanced major salivary gland cancer
por: Kang, Nai-Wen, et al.
Publicado: (2022)

Targeting the Axl and mTOR Pathway Synergizes Immunotherapy and Chemotherapy to Butylidenephthalide in a Recurrent GBM
por: Liu, Ching-Ann, et al.
Publicado: (2022)

Added value of systemic inflammation markers for monitoring response to neoadjuvant chemotherapy in breast cancer patients
por: Ke, Zi-Rui, et al.
Publicado: (2022)

Metformin and temozolomide, a synergic option to overcome resistance in glioblastoma multiforme models
por: Valtorta, Silvia, et al.
Publicado: (2017)

Anti-Invasive and Anti-Proliferative Synergism between Docetaxel and a Polynuclear Pd-Spermine Agent
por: Batista de Carvalho, Ana L. M., et al.
Publicado: (2016)

Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer
por: Chung, Young Shin, et al.
Publicado: (2017)

Tristetraprolin mediates the anti-proliferative effects of metformin in breast cancer cells
por: Pandiri, Indira, et al.
Publicado: (2016)

The role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer
por: Škof, Erik, et al.
Publicado: (2016)

Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer
por: Lee, Yong Jae, et al.
Publicado: (2020)

Change of Fagotti score is associated with outcome after neoadjuvant chemotherapy for ovarian cancer
por: Saner, Flurina Anna-Carina Maria, et al.
Publicado: (2023)

Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer
por: Hur, Jin, et al.
Publicado: (2021)

The Role of Metformin in Ovarian Cancer: Does Metformin Increase Survival in Ovarian Neoplasm?
por: Ahmed, Maimuna F, et al.
Publicado: (2021)

Optimal Lymph Node Yield for Survival Prediction in Rectal Cancer Patients After Neoadjuvant Therapy
por: Lin, Yu-Min, et al.
Publicado: (2021)

COP1 enhances ubiquitin-mediated degradation of p27(Kip1) to promote cancer cell growth
por: Choi, Hyun Ho, et al.
Publicado: (2015)

Relative Survival Benefit by Hormonal Receptor Status of Adding Trastuzumab to Neoadjuvant Chemotherapy in Breast Cancer Patients
por: Schneider, Jean, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lme9785vnn0llsrpr0h9a0ad1r